- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06109168
Correlation of SpO2/FIO2 Ratio With PaO2/FIO2 Ratio in ARDS Patients in the ICU of H. Adam Malik Hospital (MNO)
November 11, 2023 updated by: Agus pramono, RS H Adam Malik
Correlation of SpO2/FIO2 Ration With PaO2/FIO2 Ratio in Acute Respiratory Distress Syndrome (ARDS) Patients in the ICU of H. Adam Malik Hospital
This study to apprehend the relation of SpO2/FiO2 to PaO2/FiO2 in ARDS patients.
Study Overview
Status
Completed
Conditions
Detailed Description
Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition that requires immediate treatment.
The measurement of the PaO2/FiO2 (P/F) ratio is the main choice for assessing the severity of ARDS with an invasive method that requires arterial blood gas (ABG) analysis.
This study was conducted to determine the relationship between the SpO2/FiO2 ratio and the PaO2/FiO2 ratio in ARDS patients at HAM General Hospital.
This observational study used a cross-sectional research method with the total sample of 29 intubated ICU patients diagnosed with ARDS.
Patients with congestive heart failure, anemia, and systolic blood pressure <90 mmHg were excluded from the study.
The results of this study showed a positive correlation between the PaO2/FiO2 and SpO2/FiO2 ratios with a correlation coefficient of 0.955 and a p-value of 0.001.
There was a relationship between the S/F ratio and the P/F ratio in assessing the severity of ARDS with a p-value of <0.05.
This study shows that the SpO2/FiO2 (S/F) ratio has a good correlation with the PaO2/FiO2 (P/F) ratio in patients with ARDS, so it can be used as a predictor of ARDS and can be beneficial in clinical practice.
It should be noted that the SpO2/FiO2 ratio has several factors that can affect its accuracy, so careful assessment is needed.
Study Type
Observational
Enrollment (Actual)
29
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
SUmatera UTara
-
Medan, SUmatera UTara, Indonesia, 20222
- RSUP H. ADam Malik
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Intubated patients in ICU
Description
Inclusion Criteria:
- ARDS patient
- intubarted patient
Exclusion Criteria:
- Cardiac congenital disorder
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation of SpO2/FIO2 Ratio with PaO2/FIO2 Ratio in Acute Respiratory Distress Syndrome (ARDS) Patiens in the ICU of H. Adam Malik Hospital
Time Frame: June - August 2023
|
ICU patients
|
June - August 2023
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2023
Primary Completion (Actual)
August 31, 2023
Study Completion (Actual)
September 1, 2023
Study Registration Dates
First Submitted
October 25, 2023
First Submitted That Met QC Criteria
October 25, 2023
First Posted (Actual)
October 31, 2023
Study Record Updates
Last Update Posted (Actual)
November 15, 2023
Last Update Submitted That Met QC Criteria
November 11, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 536/KEPK/USU/2023
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.